XBiotech Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Company's Extensive Product Portfolio
(Thomson Reuters ONE) -
AUSTIN, Texas, June 08, 2016 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT), the
developer of True Human(TM) therapeutic antibodies, announced today that Trey
Benson has joined the company as Commercial Head, effective June 6. Benson has
more than two decades of global healthcare experience, with over 16 years of
marketing and commercial development in the pharmaceutical industry, in both
established and start-up organizations.
Reporting to XBiotech Founder, President and Chief Executive Officer John
Simard, Benson will lead the strategic commercial development for XBiotech's
extensive portfolio of True Human antibody therapies, including Xilonix(TM), the
Company's lead candidate currently in late-stage development for the treatment
of advanced colorectal cancer.
"Trey is experienced in bringing pharmaceutical products to market, with a
proven track record in achieving and beating sales growth targets," Simard said.
"We are excited to welcome Trey to the XBiotech team as we develop and implement
an innovative, growth focused commercial strategy for Xilonix and our pipeline
of products."
Benson's extensive experience has seen him serve as Vice President of Marketing
at Edgemont Pharmaceuticals, as well as nine years at Xenoport, Inc., where he
held titles of Senior Director, Strategic Product Planning; Executive Director,
Commercial Development; and as Vice President of Marketing and Commercial
Development. At Xenoport, Inc., Benson led all Horizant (gabapentin enacarbil)
promotional activities, including launch planning in co-promotion collaboration
with GSK, building the commercial organization and marketing team, and being
responsible for sales performance. Benson began his career with Abbott
Laboratories and Eli Lilly, and has been continuously recognized for his
excellence in commercialization, product strategy, and marketing.
"Joining the XBiotech team is an exciting opportunity. Our proprietary True
Human technology and pipeline of products has real potential across many
important therapeutic areas where new treatments are needed. My immediate
priority, however, is to implement a robust commercial launch plan of our
Xilonix therapy," Benson said.
XBiotech's lead product candidate, Xilonix, has the potential to change the
standard of care in treating advanced colorectal cancer. Currently in Phase III
clinical trials in the U.S. with Fast Track designation from the U.S. Food and
Drug Administration, Xilonix is specifically designed to target and neutralize
interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis (the
growth and spread of tumors), as well as mediate symptoms such as metabolic
dysregulation (e.g., a cause of muscle loss and weight loss), fatigue and
anxiety associated with advanced cancer.
About True Human(TM) Therapeutic Antibodies
Unlike previous generations of antibody therapies, XBiotech's True Human(TM)
antibodies are 100 percent human, derived from individuals who possess natural
immunity to certain diseases. With discovery and clinical programs across
multiple disease areas, XBiotech's True Human antibodies have the potential to
harness the body's natural immunity to fight disease with increased safety,
efficacy and tolerability.
The first of these therapies, Xilonix(TM), for advanced colorectal cancer, is in
Phase III clinical trials in the United States with a Fast Track designation by
the U.S. Food and Drug Administration (FDA). In Europe, Xilonix Phase III
clinical trials have been completed, and the therapy is under accelerated review
following the validation of its Market Authorization Application by the European
Medicines Agency (EMA).
About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of therapeutic
antibodies based on its True Human(TM) proprietary technology. XBiotech
currently is advancing a robust pipeline of antibody therapies to exceed the
standards of care in oncology, inflammatory conditions and infectious diseases.
Headquartered in Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more rapidly, cost-
effectively and flexibly produce new therapies urgently needed by patients
worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations
regarding management's beliefs and expectations that involve substantial risks
and uncertainties. In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "would," "could," "expects,"
"plans," "contemplate," "anticipates," "believes," "estimates," "predicts,"
"projects," "intend" or "continue" or the negative of such terms or other
comparable terminology, although not all forward-looking statements contain
these identifying words. Forward-looking statements are subject to inherent
risks and uncertainties in predicting future results and conditions that could
cause the actual results to differ materially from those projected in these
forward-looking statements. These risks and uncertainties are subject to the
disclosures set forth in the "Risk Factors" section of certain of our SEC
filings. Forward-looking statements are not guarantees of future performance,
and our actual results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ materially from the
forward-looking statements contained in this press release. Any forward-looking
statements that we make in this press release speak only as of the date of this
press release. We assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise, after the
date of this press release.
Media liaison U.S.
Mariann Caprino
+1 917 242 1087
Media liaison ex-U.S.
Jonathan Kearney
+44 20 8618 2755; Mobile: +44 7725 925 841
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: XBiotech, Inc via GlobeNewswire
[HUG#2019039]
Datum: 08.06.2016 - 17:19 Uhr
Sprache: Deutsch
News-ID 476572
Anzahl Zeichen: 7468
contact information:
Town:
Austin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 261 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"XBiotech Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Company's Extensive Product Portfolio"
steht unter der journalistisch-redaktionellen Verantwortung von
XBiotech, Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
